Search clinical trials for: INCMGA00012 (PD-1 antibody)

Total 1084 results

Beijing Friendship Hospital

Not yet recruiting

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Hemophagocytic Lymphohistiocytosis

China
Ruijin Hospital

Unknown

Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma

Nasal Type Extranodal NK/T-Cell Lymphoma

China
Sun Yat-sen University
Guangzhou No.12 People's Hospital; Kaiping Central Hospital

Withdrawn

TACE Plus PD-1 Antibody vs TACE Alone for Unresectable HCC

Hepatocellular Carcinoma

China
Jinling Hospital, China

Recruiting

Neoadjuvant Immune-based Combinations in Patients Undergoing Nephrectomy for Locally Advanced ccRCC

Neoplasms | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Carcinoma | Antineoplastic Agents | Male Urogenital Diseases | Female Urogenital Diseases | Immune Checkpoint Inhibitors | Urogenital Diseases

China
Sun Yat-sen University
Chipscreen Biosciences, Ltd.

Not yet recruiting

Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) (PCR)

Relapsed or Refractory DLBCL
Beijing Tongren Hospital

Unknown

Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell Lymphoma

NK/T Cell Lymphoma Nos

China
City of Hope Medical Center
National Cancer Institute (NCI); Imugene Limited

Active, not recruiting

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Triple-Negative Breast Carcinoma

United States
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Agenus Inc.

Completed

Study of AGEN2034 in Advanced Tumors and Cervical Cancer

Cervical Cancer | Advanced Cancer

France, United States, Belgium, Australia, Spain, Estonia, Brazil, Chile, Poland
Peking University First Hospital
YiZhou International Cancer Hospital

Unknown

Combination of Hypofractionated Proton Therapy With Immunotherapy (I-HypoPT)

Immunotherapy | Proton Therapy
Second Affiliated Hospital, School of Medicine,...

Recruiting

Single-center, Prospective Cohort Study of PD-1 Inhibitors on Clinical Outcomes of Carotid Plaques in Tumor Patients

Carotid Artery Plaque | Pd-1 Inhibitors

China
Jiangxi Provincial Cancer Hospital

Recruiting

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Nasopharyngeal Carcinoma

China
Huabo Biopharm Co., Ltd.

Recruiting

A Study of Injection HB0025 in Patients With Advanced Solid Tumors

Tumor, Subjects

United States, China
Peking University

Recruiting

HAIC Combine With Lenvatinib and PD-1 Inhibitors for Advanced HCC With PVTT

Hepatocellular Carcinoma | Portal Vein Thrombosis

China
LiuYing

Not yet recruiting

Cadonilimab as Neoadjuvant Therapy in Resectable Stage II-III MSI-H/dMMR Colorectal Cancer (MSI-H/dMMR)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Jiangsu Cancer Institute & Hospital

Active, not recruiting

Neoadjuvant Chemo-hypoRT Plus PD-1 Antibody (Tislelizumab) in Resectable LA-G/GEJ (RARE)

Gastric or Gastroesophageal Junction Adenocarcinoma

China
Shi Ming

Withdrawn

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Hepatocellular Carcinoma

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Combination of Chemotherapy Plus RT and SHR-1210 to Treat Patients With ESCC

Esophageal Cancer

China
Genentech, Inc.

Completed

A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Neoplasms

United States, Spain, Belgium, Korea, Republic of, Canada, Australia, France
Wu Jun

Recruiting

Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study

Gastric Cancer

China
Dong Wang

Not yet recruiting

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer (TC)

ESCC

China
Shanghai Pulmonary Hospital, Shanghai, China
The University of Hong Kong

Not yet recruiting

Impact of Inactivated Trivalent Influenza Vaccine on NSCLC Patients Receiving PD-1 / PD-L1 Inhibitors

Non Small Cell Lung Cancer | Influenza Vaccine

China
Robert L. Ferris, MD, PhD
Bristol-Myers Squibb

Recruiting

Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
Zhejiang University

Recruiting

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

Anti-PD-1/PD-L1 Antibodies Plus S-adenosyl-methionine Treatment in Patients With Advanced-Stage HCC

Hepatocellular Carcinoma

China
Huiqiang Huang

Recruiting

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

High-grade B-cell Lymphoma | Transformed Lymphoma | EBV-Positive DLBCL, Nos | ALK-Positive Anaplastic Large Cell Lymphoma | Non-GCB/ABC Diffuse Large B-Cell Lymphoma | Follicular Lymphoma Grade IIIb

China
Fudan University

Recruiting

Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence

Cholangiocarcinoma, Intrahepatic

China
Xiangya Hospital of Central South University

Recruiting

The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer (JSFOL)

Colonic Neoplasms | Chemotherapy Effect

China
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Advanced Solid Tumors

Tumors

France, United States, Denmark, Ireland, Italy, Turkey, United Kingdom, Canada, Brazil, Spain, Poland, Netherlands, Germany, Russian Federation, Austria, Finland, Norway, Switzerland
Symphogen A/S

Active, not recruiting

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Solid Tumor | Metastatic Cancer

United States, Canada
University of Colorado, Denver
AstraZeneca

Withdrawn

A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection

Pancreatic Cancer

United States
Fudan University

Not yet recruiting

CAPOX and PD-1 Antibody Combined With or Without Radiotherapy for MSS Locally Advanced Rectal Cancer (TORCH-iTNT)

Neoadjuvant Therapy | Locally Advanced Rectal Cancer

China
Zhejiang Cancer Hospital

Not yet recruiting

Neoadjuvant Short-course Radiotherapy Followed by the Combination of Immunotherapy and Chemotherapy in Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer

China
Fudan University

Recruiting

Sintilimab Combined With Chidamide in Treating Peripheral T Cell Lymphoma (Sincerely20)

Peripheral T-cell Lymphoma

China
University Hospital, Bordeaux

Recruiting

Treatment Pause Versus Treatment Continuation in IMDC Good or Intermediate Risk With Only One Adverse Prognostic Factor in mRCC Patients With an Objective Response at 12 Months of Treatment With PD1/ PDL1 ICIs + VEGFR-Tyrosine Kinase Inhibitors (SPICI)

Metastatic Renal Cell Carcinoma | Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score

France
Second Affiliated Hospital of Soochow University

Not yet recruiting

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

Carcinoma | Solid Tumor

China
Chinese PLA General Hospital
LinkDoc Technology (Beijing) Co. Ltd.

Unknown

A Real World Study of Anti-PD-1/PD-L1 Antibodies for the Treatment of Advanced Solid Tumors

Advanced Solid Tumors

China
Changhai Hospital

Recruiting

Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Advanced Cancer | Pancreatic Ductal Adenocarcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

Locally Advanced Non-Small Cell Lung Cancer

China
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Radical Synchronous Chemoradiotherapy With DDP/5-FU and PD-1 for Non-metastatic Rectal Squamous Cell Carcinoma

Rectal Squamous Cell Carcinoma

China
Shanghai Zhongshan Hospital

Recruiting

A Single Center Study of Donafenib Combined With PD-1 + TACE in the First-line Treatment of aHCC

Donafenib

China
Shanghai Zhongshan Hospital
Jining Medical University; Cancer Hospital of Guangxi Medical University

Active, not recruiting

GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC

Biliary Tract Carcinoma

China
University of Oxford
Vaccitech (UK) Limited

Unknown

VAccination in Early and ADvanced Prostate caNCEr (ADVANCE)

Castration-resistant Prostate Cancer | Intermediate Risk Prostate Cancer

United Kingdom
Han weidong

Unknown

Anti-PD-1 Antibody Alone or in Combination With Decitabine/Chemotherapy in Relapsed or Refractory Malignancies

Malignancies Multiple

China
Jason J. Luke, MD

Recruiting

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Melanoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | NSCLC | Advanced Solid Tumors | Cholangiocarcinoma | Bladder Cancer | Renal Cancer | Anal Cancer | Merkel Cell Carcinoma | HNSCC

United States
Second Affiliated Hospital, School of Medicine,...

Recruiting

Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma

Carcinoma, Hepatocellular

China
Peking University Cancer Hospital & Institute

Recruiting

Study to Evaluate OrienX010 in Combination With JS001 in the Treatment of Stage IV (M1c) Liver Metastasis From Melanoma

Melanoma

China
Tianjin Medical University Cancer Institute and...

Unknown

Study of Chemotherapy Combination With Autologous Cell Immunotherapy in the Advanced Lung Cancer

IIIB/IIIC/IV Lung Cancer

China
Chinese PLA General Hospital
Zhejiang University

Recruiting

Combination of CAR-DC Vaccine and ICIs in Malignant Tumors

Lymphoma | Solid Tumor, Adult | EphA2 Overexpression | TP53 R273H | TP53 R175H | TP53 R248Q | TP53 R249S

China
Sun Yat-sen University

Recruiting

Anti-PD-1 Immunotherapy Combined With SBRT for Patients With Oligometastatic ESCC

Esophageal Squamous Cell Carcinoma | Oligometastatic Disease

China

Search clinical trials for: INCMGA00012 (PD-1 antibody)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bangladesh

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations